Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of κB Kinase and Inflammasome-Mediated Interleukin-1β Secretion

Figure 4

Inhibition of inflammasome-mediated IL-1β secretion by auranofin. (a) Effects of auranofin on the protein expression of pro-IL-1β and cleaved IL-1β. BMMs were primed with LPS (100 ng/mL) for 4 h and further incubated with 1 mM ATP and nivocasan (3-30 μM) for 1 h. (b) Effect of the inflammasome inhibitor (nivocasan) on osteoclast differentiation. The left panel shows the representative images of TRAP stainings, and the number of TRAP-positive multinuclear cells was illustrated in the right panel (). (c) Effects of nivocasan on NFATc1 and c-Fos expression in RANKL-treated BMMs. (d) IL-1β ELISA results (). The secreted IL-1β levels were determined in culture media from J774.1A cells and BMDMs incubated with 1 mM ATP and auranofin (0.3-3 μM) for 1 h followed by preincubation with 100 ng/mL LPS for 4 h. (e) Cell lysates from J774.1A cells (left) and BMDMs (right) were analyzed for protein expression of pro-IL-1β and cleaved IL-1β by immunoblottings. compared with the control group; compared with the RANKL-treated group.

(a)

(b)

(c)

(d)

(e)